XE recombination arrives
Bottom line, Im not worried, but it is interesting
VOCs
What is XE?
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf
https://deadline.com/wp-content/uploads/2022/03/20220329_Weekly_Epi_Update_85.pdf
XE strain is a recombinant variant of BA.1 and BA.2
Mutation
An error is incorporated in the viral genome
Recombination
Coinfecting viruses exchange genetic information, creating a novel virus
Changes to variant classification system
Variant of Concern label
a detrimental change in biological properties (changes in transmissibility, severity or immune evasion) compared to the current dominant variant(s); and
a growth rate potentially compatible with maintaining transmission and/or displacing the current dominant variant.
designate new variants based on genomic features and growth
X = BA.1
E = BA.2
X = Delta
F = Delta
Two are a combination of Delta and BA.1
XD and XF
XD, few cases detected in France, Belgium, Denmark
XT, small cluster detected in UK, (before 15th Feb)
One recombination of BA.1 and BA.2
XE is a BA.1/BA.2 recombinant
XE evidence of community transmission within England
currently less than 1% of total sequenced cases
Using the most recent data up to 16 March 2022
XE has a growth rate 9.8% above that of BA.2
Per week
XE biology
763 XE sequences in the UK data
XE is a BA.1 and BA.2 recombinant
3 mutations that are not present in all BA.1 or BA.2 sequences
BA.2 latest
SGTP is a reasonable proxy for BA.2
England on 20 March 2022, 93.7% BA.2
England on 6th March 2022, 82.6% BA.2
Growth rate of BA.2
Increased growth rate compared to BA.1 in all regions of England
Growth rate, 75% greater relative growth for BA.2 compared to BA.1.
GR = 0.753 per week
Hospitalisation
No evidence of a greater risk of hospitalisation following infection with BA.2 compared to BA.1.
SARS-CoV-2 Immunity and Reinfection EvaluatioN (SIREN)
90 day gap
N = 44,000 healthcare workers, recruited from 135 sites
Now highly vaccinated (more than 95%)
Two weekly PVR testing
27th December 2021 to 16th January 2022
N = 496,228 cases of PCR confirmed SARS-CoV-2 infection
186,896 BA.1 confirmed cases with genome sequencing
Thirty-one of these cases had another subsequent sequenced
but there are no early indications of a specific reinfection issue with this scenario.
Видео XE recombination arrives канала Dr. John Campbell
VOCs
What is XE?
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf
https://deadline.com/wp-content/uploads/2022/03/20220329_Weekly_Epi_Update_85.pdf
XE strain is a recombinant variant of BA.1 and BA.2
Mutation
An error is incorporated in the viral genome
Recombination
Coinfecting viruses exchange genetic information, creating a novel virus
Changes to variant classification system
Variant of Concern label
a detrimental change in biological properties (changes in transmissibility, severity or immune evasion) compared to the current dominant variant(s); and
a growth rate potentially compatible with maintaining transmission and/or displacing the current dominant variant.
designate new variants based on genomic features and growth
X = BA.1
E = BA.2
X = Delta
F = Delta
Two are a combination of Delta and BA.1
XD and XF
XD, few cases detected in France, Belgium, Denmark
XT, small cluster detected in UK, (before 15th Feb)
One recombination of BA.1 and BA.2
XE is a BA.1/BA.2 recombinant
XE evidence of community transmission within England
currently less than 1% of total sequenced cases
Using the most recent data up to 16 March 2022
XE has a growth rate 9.8% above that of BA.2
Per week
XE biology
763 XE sequences in the UK data
XE is a BA.1 and BA.2 recombinant
3 mutations that are not present in all BA.1 or BA.2 sequences
BA.2 latest
SGTP is a reasonable proxy for BA.2
England on 20 March 2022, 93.7% BA.2
England on 6th March 2022, 82.6% BA.2
Growth rate of BA.2
Increased growth rate compared to BA.1 in all regions of England
Growth rate, 75% greater relative growth for BA.2 compared to BA.1.
GR = 0.753 per week
Hospitalisation
No evidence of a greater risk of hospitalisation following infection with BA.2 compared to BA.1.
SARS-CoV-2 Immunity and Reinfection EvaluatioN (SIREN)
90 day gap
N = 44,000 healthcare workers, recruited from 135 sites
Now highly vaccinated (more than 95%)
Two weekly PVR testing
27th December 2021 to 16th January 2022
N = 496,228 cases of PCR confirmed SARS-CoV-2 infection
186,896 BA.1 confirmed cases with genome sequencing
Thirty-one of these cases had another subsequent sequenced
but there are no early indications of a specific reinfection issue with this scenario.
Видео XE recombination arrives канала Dr. John Campbell
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
DNR at 38 years of ageMidazolam deathsConfirmed horrifying scandalDo not resuscitate ordersNew US Vit D researchWHO power grabWHO new powers concernExcess deaths, parliament questionsViral origins, the stitchupWHO New Health RegulationsInternational concern, excess deathsVaccine damage, Sir Christopher ChopeVit D and prostate cancerAppalling vaccine injuryAgreement on aspirationTGA document revelationsPandemic unnecessary deaths, the dataGovernment Counter Disinformation UnitHeart deaths in AustraliaExcess deaths in young adults, 2022 dataWHO’s Global Digital Health Certification Network